Compare RBKB & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RBKB | KPTI |
|---|---|---|
| Founded | 1860 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.6M | 172.6M |
| IPO Year | 2018 | 2013 |
| Metric | RBKB | KPTI |
|---|---|---|
| Price | $15.59 | $8.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $14.67 |
| AVG Volume (30 Days) | 9.3K | ★ 1.3M |
| Earning Date | 04-24-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 215.00 | N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | $2,984,000.00 | ★ $146,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $22.36 |
| P/E Ratio | $16.88 | ★ N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $9.41 | $3.65 |
| 52 Week High | $16.50 | $10.99 |
| Indicator | RBKB | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 55.34 | 58.78 |
| Support Level | $15.04 | $5.43 |
| Resistance Level | $16.50 | $9.00 |
| Average True Range (ATR) | 0.26 | 0.71 |
| MACD | -0.04 | 0.28 |
| Stochastic Oscillator | 55.13 | 93.23 |
Rhinebeck Bancorp Inc is the holding company for Rhinebeck Bank, which is a New York-chartered stock savings bank. It provides a full range of banking and financial services to consumer and commercial customers. Financial services, including investment advisory and financial product sales, are offered through a division of the Bank doing business as Rhinebeck Asset Management. The Bank's primary business activity is accepting deposits from the general public and using those funds together with borrowings, to originate commercial real estate loans (which include multi-family real estate loans and commercial construction loans), commercial business loans and indirect automobile loans, and to purchase one- to four-family residential real estate loans and investment securities.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).